Jiangsu Recbio Technology (HKG:2179) posted a loss attributable to owners of 610.4 million yuan for 2025, widening from 562.4 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.
Loss per share came in at 1.15 yuan, compared with 1.16 yuan a year ago.
Revenue was 12.7 million yuan, compared with nil revenue reported in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments